Hansa Biopharma Ab Is A Biopharmaceutical Company Based In Lundswedenfocused On Developing Innovative Treatments For Rare Immunological Conditionsthe Company Utilizes Its Proprietary Antibody Cleaving Enzyme Technology Platformparticularly Imlifidaseto Target Pathogenic Antibodies Involved In Various Diseasesimlifidase Is Approved In Europe For Desensitization In Kidney Transplantationhelping Highly Sensitized Patients Receive Transplantsa Biologics License Application For The U Smarket Is Planned For 2025 Hansa S Pipeline Includes Seven Clinical Trials Aimed At Autoimmune Disordersgene Therapyand Expanding Transplantation Applicationsthe Company Collaborates With Partners Like Sarepta Therapeutics And Askbio To Enhance Gene Therapy Delivery Mechanismshansa Operates In Major European Markets And Is Preparing For U Smarket Entryfocusing On Geographic Expansion And Label Extensions For Imlifidasewith A Diverse Team And A Commitment To Sustainabilityhansa Is Backed By Specialist Investors And Has Secured Funding Through 2026
